tiprankstipranks
ImmuPharma PLC (GB:IMM)
LSE:IMM

ImmuPharma Stock Analysis & Ratings

GB:IMM Stock Chart & Stats

Day’s Range0p - 0p
52-Week Range4.80p - 10.90p
Previous Close5.65p
Volume960.37K
Average Volume (3M)1.63M
Market CapN/A
Enterprise ValueN/A
P/E Ratio-1.9
Beta0.72
Next EarningsSep 28, 2022
EPS ForecastN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
1Y Price TargetN/A
Smart ScoreN/A


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

GB:IMM FAQ

What was ImmuPharma’s price range in the past 12 months?
ImmuPharma lowest stock price was 4.80p and its highest was 10.90p in the past 12 months.
    What is ImmuPharma’s market cap?
    Currently, no data Available
    What is ImmuPharma’s price target?
    Currently, no data Available
    What do analysts say about ImmuPharma?
    Not enough analysts have published a price target to provide an average price target.
    When is ImmuPharma’s upcoming earnings report date?
    ImmuPharma’s upcoming earnings report date is Sep 28, 2022 which is in 90 days.
      How were ImmuPharma’s earnings last quarter?
      ImmuPharma released its earnings results on May 25, 2022. The company reported -1.8p earnings per share for the quarter, missing the consensus estimate of N/A by -1.8p.
        Is ImmuPharma overvalued?
        According to Wall Street analysts ImmuPharma’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does ImmuPharma pay dividends?
          ImmuPharma does not currently pay dividends.
          What is ImmuPharma’s EPS estimate?
          ImmuPharma’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does ImmuPharma have?
          ImmuPharma has 284,984,920 shares outstanding.
            What happened to ImmuPharma’s price movement after its last earnings report?
            ImmuPharma reported an EPS of -1.8p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -9.864%.
              Which hedge fund is a major shareholder of ImmuPharma?
              Currently, no hedge funds are holding shares in GB:IMM

              ---

              ImmuPharma Stock Analysis

              Smart Score
              N/A
              Not Ranked
              1
              2
              3
              4
              5
              6
              7
              8
              9
              10
              Price Target
              No data currently available

              Analyst Forecast

              N/A
              Currently Not Enough Data Available

              Blogger Sentiment

              N/A
              Currently Not Enough Data Available

              Insider Transactions

              N/A
              Currently Not Enough Data Available

              News Sentiment

              N/A
              Currently Not Enough Data Available

              Technicals

              SMA
              Negative
              20 days / 200 days
              Momentum
              -33.60%
              12-Months-Change

              Fundamentals

              Return on Equity
              -116.20%
              Trailing 12-Months
              Asset Growth
              -45.05%
              Trailing 12-Months
              This stock does not have enough of the key information we need to rate it accurately. Smart Score is calculated for stocks traded in Nasdaq, NYSE, TSE and LSE with a market cap above $30M and average 3 months trading volume above $30K.
              Learn more about TipRanks Smart Score

              Company Description

              ImmuPharma PLC

              ImmuPharma PLC is a drug discovery and development company. The company is focused on the development of drugs based on peptide therapeutics, to treat serious medical conditions such as autoimmune diseases. It has drug candidates in development, over two platform technologies and approximately 70 patents. Lupuzor is the company's drug candidate and is a treatment for lupus, and life-threatening autoimmune disease. The company's pipeline includes novel peptide-based therapeutics within four therapy areas: Autoimmunity; Anti-Infectives; Metabolism and Cancer.

              ---
              Similar Stocks
              Company
              Price & Change
              Follow
              ReNeuron Group
              Faron Pharmaceuticals Oy
              Scancell Holdings

              Popular Stocks

              ---
              What's Included in PREMIUM?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis